Table 2. Multivariate analysis of factors predicting death at 6 weeks among patients with mucormycosis, India*.

Variables	Survivors, n = 177	Non-survivors, n = 110	Odds ratio (95% CI)	p value
Mean age, y (SD)	52.6 (15.1)	54.7 (14.0)	1.02 (1.00–1.04)	0.03
Underlying disease
None	10 (5.6)	9 (8.2)	Referent	Referent
Isolated COVID-19	42 (23.7)	19 (17.3)	0.56 (0.17–1.83)	0.34
Diabetes mellitus	109 (61.6)	71 (64.5)	0.92 (0.32–2.64)	0.88
Traumatic inoculation	8 (4.5)	4 (3.6)	1.30 (0.25–6.80)	0.76
Others	5 (2.8)	3 (2.7)	1.20 (0.18–7.81)	0.85
Renal transplantation	1 (0.6)	2 (1.8)	6.87 (0.42–113.19)	0.18
Hematological malignancy	2 (1.1)	2 (1.8)	1.60 (0.14–18.72)	0.71
Site of involvement
Rhino-orbital	117 (66.1)	50 (45.5)	Referent	Referent
Rhino-orbito-cerebral	39 (22)	39 (35.5)	2.39 (1.30–4.40)	0.005
Pulmonary	8 (4.5)	14 (12.7)	3.26 (1.05–10.11)	0.04
Other†	13 (7.3)	7 (6.4)	1.29 (0.43–3.86)	0.64
Admission to the intensive care unit	32 (18.1)	35 (31.8)	2.87 (1.43–5.75)	0.003
Combined medical surgical therapy	135 (76.3)	69 (62.7)	0.77 (0.41–1.45)	0.41
Combination of antifungals
Single antifungal drug	95 (53.7)	88 (80)	Referent	Referent
Concurrent	9 (5.1)	5 (4.5)	0.37 (0.09–1.44)	0.15
Sequential	73 (41.2)	17 (15.5)	0.17 (0.87–0.35)	0.0001

*Values are no. (%) except as indicated. Bold text indicates statistical significance. COVID-19, coronavirus disease. †Includes cutaneous, stomach, disseminated, or other.